Outcomes of Concomitant Bypass Surgery in Septal Myectomy

To investigate clinical characteristics and survival outcomes of patients with obstructive hypertrophic cardiomyopathy who underwent concomitant coronary artery bypass grafting during septal myectomy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertrophic Cardiomyopathy Aortic Stenosis, Subvalvular Aortic Valve Disease Aortic Valve Stenosis Arterial Occlusive Diseases Arteriosclerosis Cardiomyopathies Cardiomyopathy, Hypertrophic Cardiovascular Abnormalities Cardiovascular Diseases Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Coronary Artery Disease Coronary Disease Coronary Vessel Anomalies Heart Defects, Congenital Heart Diseases Heart Valve Diseases Myocardial Bridging Myocardial Ischemia Vascular Diseases

Age range

8 year–90 year

Sex eligibility

All sexes

Study type

Observational

About this study

Surgical septal myectomy (SM) is an effective approach for treating patients with drug-refractory obstructive hypertrophic cardiomyopathy (HCM).However, numerous patients with HCM exhibit concurrent ischemic heart disease, including atherosclerotic coronary artery disease (CAD) and myocardial bridging (MB). Although patients with HCM have been known to possess diminished coronary flow reserve,additional CAD can worsen myocardial ischemia, contributing to an unfavorable prognosis.MB, although infrequent, may affect diastolic heart perfusion, leading to angina and even sudden death.Current guidelines recommend revascularization for ischemic heart disease caused by CAD and MB.However, the impact of concomitant coronary revascularization during HCM management remains unclear. In this study, we analyzed the clinical characteristics and surgical scenarios of patients who underwent concomitant coronary artery bypass grafting (CABG) during ventricular SM and investigated their prognosis.

Patient clinical and survival data from 2009-2020 were retrospectively reviewed. The median follow-up period was 5.1 years. All-cause mortality was the primary endpoint.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnosis of obstructive hypertrophic cardiomyopathy.
Undergo ventricular septal resection and cardiac bypass surgery at the same time.

Exclusion criteria

Incomplete surgical and follow-up data

Treatment and study plan

CABG during myectomy

Procedure

To explore the effect of CABG during myectomy. No control group

Primary outcomes

all-cause mortality

Time frame: through study completion, an average of 5 year

death because of any reason

Secondary outcomes

cardiac-related deaths and readmission

Time frame: through study completion, an average of 5 year

deaths and readmission because of heart failure, stoke, and etc.

Sponsors and collaborators

Lead sponsor

Chinese Academy of Medical Sciences, Fuwai Hospital

Other

Registry information

Official study title

Establishing a Database of Patients Undergoing Surgery for Hypertrophic Cardiomyopathy (Concomitant Bypass Surgery)

Important dates

Study start: 2009
Primary completion: 2020
Study completion: 2023
First posted: Apr 9, 2024
Registry last updated: Apr 9, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed